A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Efficacy, Safety, and Dosing Regimen Selection of Multiple Intravenous Infusions of PRX-115 With and Without Methotrexate Versus Placebo in Adult Patients With Gout (RELEASE)
Latest Information Update: 13 Jun 2026
At a glance
- Drugs Methotrexate (Primary) ; PRX-115 (Primary)
- Indications Gout
- Focus Therapeutic Use
- Acronyms RELEASE
- Sponsors Protalix Biotherapeutics
Most Recent Events
- 13 May 2026 According to Protalix BioTherapeutics media release, the company expects to continue to incur R&D expenses as the RELEASE study progresses.
- 18 Mar 2026 According to Protalix BioTherapeutics media release, The Company anticipates top-line results in the second half of 2027.
- 25 Feb 2026 Status changed from not yet recruiting to recruiting.